EGFR and non-small cell lung carcinoma: In another phase II study of NCT03513666, when receiving a combination of toripalimab and chemotherapy, the objective response rate (ORR) was 50%, and the median PFS was 7 months for EGFR-mutant NSCLC after TKI resistance (42).